Boston Scientific (BSX $7.35 +9.6%) reported second quarter earnings of $0.17 per share, excluding non-recurring items, $0.09 better than the Capital IQ Consensus Estimate of $0.08.
Revenues rose 2.4% year/year to $1.98 billion versus the $1.94 billion consensus.
Co issues mixed guidance for Q3, sees EPS of $0.11-0.14, excluding non-recurring items, vs. $0.09 Capital IQ Consensus Estimate; Company sees Q3 revenues of $1.870-1.970 billion versus. $1.9 billion Capital IQ Consensus Estimate.
Co issues mixed guidance for FY11, sees EPS of $0.64-.070, excluding non-recurring items, vs. $0.42 Capital IQ Consensus Estimate and up from prior range of $0.58-0.68; sees FY11 revs of $7.675-7.875 vs. $7.74 billion Capital IQ Consensus Estimate.
Co's Board of Directors has also approved a new program authorizing the repurchase of up to $1.0 billion of its common stock and re-approving the ~37 million shares remaining under an existing share repurchase program.






